UCB SA (UCBJF)
| Market Cap | 53.13B |
| Revenue (ttm) | 9.09B |
| Net Income (ttm) | 1.83B |
| Shares Out | n/a |
| EPS (ttm) | 9.43 |
| PE Ratio | 29.04 |
| Forward PE | 22.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19 |
| Average Volume | 398 |
| Open | 285.29 |
| Previous Close | 291.41 |
| Day's Range | 285.29 - 285.29 |
| 52-Week Range | 168.65 - 345.39 |
| Beta | 0.23 |
| RSI | 43.71 |
| Earnings Date | Jul 30, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial numbers in EURNews
UCB: United Community Bank CFO to Retire, Transition Underway
UCB: United Community Bank CFO to Retire, Transition Underway
UCB Q1 2026 Earnings Call Transcript
UCB Q1 2026 Earnings Call Transcript
United Community Banks Inc (UCB) Q1 2026 Earnings Call Highlights: Strong Financial Performance ...
United Community Banks Inc (UCB) Q1 2026 Earnings Call Highlights: Strong Financial Performance and Strategic Growth Initiatives
United Community Banks Delivers 12% Revenue Growth in Q1 2026
Narrow Miss. United Community Banks, Inc. (UCB) reported Q1 2026 operating earnings of $0.70 per share, falling just short of the $0.71 consensus estimate b... The post United Community Banks Delivers...
UCB Reports Strong Q1 Revenue Exceeding Expectations
UCB Reports Strong Q1 Revenue Exceeding Expectations
Here's What Key Metrics Tell Us About United Community Banks (UCB) Q1 Earnings
Although the revenue and EPS for United Community Banks (UCB) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare wit...
United Community Banks (UCB) Announces Merger with Peach State Bancshares
United Community Banks (UCB) Announces Merger with Peach State Bancshares
United Community Banks (UCB) Q1 2026: EPS $0.69 Misses vs $0.70 Est, Revenue $276. ...
United Community Banks (UCB) Q1 2026: EPS $0.69 Misses vs $0.70 Est, Revenue $276.5M Beats vs $272.75M Est -- Overvalued by 7.0%? GF Score 72/100
United Community Banks Releases Q1 2026 Financial Results
United Community Banks, Inc. (UCB) reported Q1 2026 operating earnings of $0.70 per share, missing the $0.71 consensus estimate (miss by 1.4%). The post United Community Banks Releases Q1 2026 Financi...
United Community Banks Inc. Q1 Profit Rises
(RTTNews) - United Community Banks Inc. (UCB) announced earnings for its first quarter that Increases, from the same period last year
UCB Acquires Neurona Therapeutics for Up to $1.15 Billion
UCB Acquires Neurona Therapeutics for Up to $1.15 Billion
UCB (UCBJY) Announces Acquisition of Neurona Therapeutics for $1.15 Billion
UCB (UCBJY) Announces Acquisition of Neurona Therapeutics for $1.15 Billion
United Community Banks Inc (UCB) Stock Up 4.1% but GF Value Says Overvalued -- GF Score: 71/100
United Community Banks Inc (UCB) Stock Up 4.1% but GF Value Says Overvalued -- GF Score: 71/100
United Community Banks Inc (UCB) Shares Up 3.17% on Apr 9
United Community Banks Inc (UCB) Shares Up 3.17% on Apr 9
UCB Gets Upgraded to 'Outperform' by Keefe, Bruyette & Woods | UCB Stock News
UCB Gets Upgraded to 'Outperform' by Keefe, Bruyette & Woods | UCB Stock News
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
UCB SA Earnings Call Transcript: H2 2025
Net sales surged 35% year-over-year, led by Bimzelx and four other growth drivers, with strong pipeline progress and a robust financial position. 2026 guidance anticipates continued high single to low double-digit revenue growth and margin expansion, supported by strategic investments and portfolio differentiation.
UCB SA Transcript: 44th Annual J.P. Morgan Healthcare Conference
A decade of growth is anticipated, driven by five key products in immunology and neurology, robust R&D investment, and a strong pipeline. Market access for BIMZELX is expanding, with new indications and head-to-head studies expected to fuel further growth.
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...
UCB SA Earnings Call Transcript: H1 2025
First-half 2025 saw 26% net sales growth, led by BIMZELX and strong pipeline progress. Upgraded full-year guidance reflects confidence in continued momentum, despite pricing and currency headwinds. BIMZELX's global expansion and new indications underpin robust financial and operational performance.
UCB SA Earnings Call Transcript: H2 2024
2024 saw a robust financial turnaround with 17% revenue growth, strong performance from key assets like BIMZELX and FINTEPLA, and a positive outlook for 2025 with double-digit revenue and margin expansion expected. Strategic divestments and pipeline progress further strengthened the growth platform.
UCB SA Earnings Call Transcript: H1 2024
Net sales grew 11% year-over-year, driven by strong launches of five key assets and robust global uptake, especially for BIMZELX and RYSTIGGO. EBITDA margin was 23% amid increased investment, with 2024 revenue expected at the top end of guidance and ambitious 2025 targets reaffirmed.